Active vaccination against interleukin-5 as long-term treatment for insect-bite hypersensitivity in horses. Fettelschoss-Gabriel, A., Fettelschoss, V., Olomski, F., Birkmann, K., Thoms, F., Bühler, M., Kummer, M., Zeltins, A., Kündig, T. M., & Bachmann, M. F. Allergy, 74(3):572–582, March, 2019. Number: 3![Active vaccination against interleukin-5 as long-term treatment for insect-bite hypersensitivity in horses [link]](https://bibbase.org/img/filetypes/link.svg "link")
Paper doi abstract bibtex 2 downloads Background Insect-bite hypersensitivity (IBH) in horses is a chronic allergic dermatitis caused by insect bites. Horses suffer from pruritic skin lesions, caused by type-I/type-IV allergic reactions accompanied by prominent eosinophil infiltration into the skin. Interleukin-5 (IL-5) is the key cytokine for eosinophils and we have previously shown that targeting IL-5 by vaccination reduces disease symptoms in horses. Objective Here, we analyzed the potential for long-term therapy by assessing a second follow-up year of the previously published study. Methods The vaccine consisted of equine IL-5 (eIL-5) covalently linked to a cucumber mosaic virus-like particle (VLP) containing a universal T cell epitope (CuMVTT) using a semi-crossover design to follow vaccinated horses during a second treatment season. Thirty Icelandic horses were immunized with 300 μg of eIL-5-CuMVTT without adjuvant. Results The vaccine was well tolerated and did not reveal any safety concerns throughout the study. Upon vaccination, all horses developed reversible anti-eIL-5 auto-antibody titers. The mean course of eosinophil levels was reduced compared to placebo treatment leading to significant reduction of clinical lesion scores. Horses in their second vaccination year showed a more pronounced improvement of disease symptoms when compared to first treatment year, most likely due to more stable antibody titers induced by a single booster injection. Hence, responses could be maintained over two seasons and the horses remained protected against disease symptoms. Conclusion Yearly vaccination against IL-5 may be a long-term solution for the treatment of IBH and other eosinophil-mediated diseases in horses and other species including humans.
@article{fettelschoss-gabriel_active_2019,
title = {Active vaccination against interleukin-5 as long-term treatment for insect-bite hypersensitivity in horses},
volume = {74},
issn = {01054538},
url = {http://doi.wiley.com/10.1111/all.13659},
doi = {10.1111/all.13659},
abstract = {Background
Insect-bite hypersensitivity (IBH) in horses is a chronic allergic dermatitis caused by insect bites. Horses suffer from pruritic skin lesions, caused by type-I/type-IV allergic reactions accompanied by prominent eosinophil infiltration into the skin. Interleukin-5 (IL-5) is the key cytokine for eosinophils and we have previously shown that targeting IL-5 by vaccination reduces disease symptoms in horses.
Objective
Here, we analyzed the potential for long-term therapy by assessing a second follow-up year of the previously published study.
Methods
The vaccine consisted of equine IL-5 (eIL-5) covalently linked to a cucumber mosaic virus-like particle (VLP) containing a universal T cell epitope (CuMVTT) using a semi-crossover design to follow vaccinated horses during a second treatment season. Thirty Icelandic horses were immunized with 300 μg of eIL-5-CuMVTT without adjuvant.
Results
The vaccine was well tolerated and did not reveal any safety concerns throughout the study. Upon vaccination, all horses developed reversible anti-eIL-5 auto-antibody titers. The mean course of eosinophil levels was reduced compared to placebo treatment leading to significant reduction of clinical lesion scores. Horses in their second vaccination year showed a more pronounced improvement of disease symptoms when compared to first treatment year, most likely due to more stable antibody titers induced by a single booster injection. Hence, responses could be maintained over two seasons and the horses remained protected against disease symptoms.
Conclusion
Yearly vaccination against IL-5 may be a long-term solution for the treatment of IBH and other eosinophil-mediated diseases in horses and other species including humans.},
language = {en},
number = {3},
urldate = {2019-12-02},
journal = {Allergy},
author = {Fettelschoss-Gabriel, Antonia and Fettelschoss, Victoria and Olomski, Florian and Birkmann, Katharina and Thoms, Franziska and Bühler, Maya and Kummer, Martin and Zeltins, Andris and Kündig, Thomas M. and Bachmann, Martin F.},
month = mar,
year = {2019},
note = {Number: 3},
keywords = {Application - Allergy Research, Application - Antibody Validation / Epitope Mapping, Application - Vaccine Development, Country - Latvia, Country - Switzerland, Country - United Kingdom, Other Organisms, PEPperCHIP - Customized - Linear, PEPperMAP - Epitope Mapping - Linear, Sample Type - Serum},
pages = {572--582},
}
Downloads: 2
{"_id":"XyTCQHnadibQrmdJi","bibbaseid":"fettelschossgabriel-fettelschoss-olomski-birkmann-thoms-bhler-kummer-zeltins-etal-activevaccinationagainstinterleukin5aslongtermtreatmentforinsectbitehypersensitivityinhorses-2019","authorIDs":[],"author_short":["Fettelschoss-Gabriel, A.","Fettelschoss, V.","Olomski, F.","Birkmann, K.","Thoms, F.","Bühler, M.","Kummer, M.","Zeltins, A.","Kündig, T. M.","Bachmann, M. F."],"bibdata":{"bibtype":"article","type":"article","title":"Active vaccination against interleukin-5 as long-term treatment for insect-bite hypersensitivity in horses","volume":"74","issn":"01054538","url":"http://doi.wiley.com/10.1111/all.13659","doi":"10.1111/all.13659","abstract":"Background Insect-bite hypersensitivity (IBH) in horses is a chronic allergic dermatitis caused by insect bites. Horses suffer from pruritic skin lesions, caused by type-I/type-IV allergic reactions accompanied by prominent eosinophil infiltration into the skin. Interleukin-5 (IL-5) is the key cytokine for eosinophils and we have previously shown that targeting IL-5 by vaccination reduces disease symptoms in horses. Objective Here, we analyzed the potential for long-term therapy by assessing a second follow-up year of the previously published study. Methods The vaccine consisted of equine IL-5 (eIL-5) covalently linked to a cucumber mosaic virus-like particle (VLP) containing a universal T cell epitope (CuMVTT) using a semi-crossover design to follow vaccinated horses during a second treatment season. Thirty Icelandic horses were immunized with 300 μg of eIL-5-CuMVTT without adjuvant. Results The vaccine was well tolerated and did not reveal any safety concerns throughout the study. Upon vaccination, all horses developed reversible anti-eIL-5 auto-antibody titers. The mean course of eosinophil levels was reduced compared to placebo treatment leading to significant reduction of clinical lesion scores. Horses in their second vaccination year showed a more pronounced improvement of disease symptoms when compared to first treatment year, most likely due to more stable antibody titers induced by a single booster injection. Hence, responses could be maintained over two seasons and the horses remained protected against disease symptoms. Conclusion Yearly vaccination against IL-5 may be a long-term solution for the treatment of IBH and other eosinophil-mediated diseases in horses and other species including humans.","language":"en","number":"3","urldate":"2019-12-02","journal":"Allergy","author":[{"propositions":[],"lastnames":["Fettelschoss-Gabriel"],"firstnames":["Antonia"],"suffixes":[]},{"propositions":[],"lastnames":["Fettelschoss"],"firstnames":["Victoria"],"suffixes":[]},{"propositions":[],"lastnames":["Olomski"],"firstnames":["Florian"],"suffixes":[]},{"propositions":[],"lastnames":["Birkmann"],"firstnames":["Katharina"],"suffixes":[]},{"propositions":[],"lastnames":["Thoms"],"firstnames":["Franziska"],"suffixes":[]},{"propositions":[],"lastnames":["Bühler"],"firstnames":["Maya"],"suffixes":[]},{"propositions":[],"lastnames":["Kummer"],"firstnames":["Martin"],"suffixes":[]},{"propositions":[],"lastnames":["Zeltins"],"firstnames":["Andris"],"suffixes":[]},{"propositions":[],"lastnames":["Kündig"],"firstnames":["Thomas","M."],"suffixes":[]},{"propositions":[],"lastnames":["Bachmann"],"firstnames":["Martin","F."],"suffixes":[]}],"month":"March","year":"2019","note":"Number: 3","keywords":"Application - Allergy Research, Application - Antibody Validation / Epitope Mapping, Application - Vaccine Development, Country - Latvia, Country - Switzerland, Country - United Kingdom, Other Organisms, PEPperCHIP - Customized - Linear, PEPperMAP - Epitope Mapping - Linear, Sample Type - Serum","pages":"572–582","bibtex":"@article{fettelschoss-gabriel_active_2019,\n\ttitle = {Active vaccination against interleukin-5 as long-term treatment for insect-bite hypersensitivity in horses},\n\tvolume = {74},\n\tissn = {01054538},\n\turl = {http://doi.wiley.com/10.1111/all.13659},\n\tdoi = {10.1111/all.13659},\n\tabstract = {Background\nInsect-bite hypersensitivity (IBH) in horses is a chronic allergic dermatitis caused by insect bites. Horses suffer from pruritic skin lesions, caused by type-I/type-IV allergic reactions accompanied by prominent eosinophil infiltration into the skin. Interleukin-5 (IL-5) is the key cytokine for eosinophils and we have previously shown that targeting IL-5 by vaccination reduces disease symptoms in horses.\n\nObjective\nHere, we analyzed the potential for long-term therapy by assessing a second follow-up year of the previously published study.\n\nMethods\nThe vaccine consisted of equine IL-5 (eIL-5) covalently linked to a cucumber mosaic virus-like particle (VLP) containing a universal T cell epitope (CuMVTT) using a semi-crossover design to follow vaccinated horses during a second treatment season. Thirty Icelandic horses were immunized with 300 μg of eIL-5-CuMVTT without adjuvant.\n\nResults\nThe vaccine was well tolerated and did not reveal any safety concerns throughout the study. Upon vaccination, all horses developed reversible anti-eIL-5 auto-antibody titers. The mean course of eosinophil levels was reduced compared to placebo treatment leading to significant reduction of clinical lesion scores. Horses in their second vaccination year showed a more pronounced improvement of disease symptoms when compared to first treatment year, most likely due to more stable antibody titers induced by a single booster injection. Hence, responses could be maintained over two seasons and the horses remained protected against disease symptoms.\n\nConclusion\nYearly vaccination against IL-5 may be a long-term solution for the treatment of IBH and other eosinophil-mediated diseases in horses and other species including humans.},\n\tlanguage = {en},\n\tnumber = {3},\n\turldate = {2019-12-02},\n\tjournal = {Allergy},\n\tauthor = {Fettelschoss-Gabriel, Antonia and Fettelschoss, Victoria and Olomski, Florian and Birkmann, Katharina and Thoms, Franziska and Bühler, Maya and Kummer, Martin and Zeltins, Andris and Kündig, Thomas M. and Bachmann, Martin F.},\n\tmonth = mar,\n\tyear = {2019},\n\tnote = {Number: 3},\n\tkeywords = {Application - Allergy Research, Application - Antibody Validation / Epitope Mapping, Application - Vaccine Development, Country - Latvia, Country - Switzerland, Country - United Kingdom, Other Organisms, PEPperCHIP - Customized - Linear, PEPperMAP - Epitope Mapping - Linear, Sample Type - Serum},\n\tpages = {572--582},\n}\n\n","author_short":["Fettelschoss-Gabriel, A.","Fettelschoss, V.","Olomski, F.","Birkmann, K.","Thoms, F.","Bühler, M.","Kummer, M.","Zeltins, A.","Kündig, T. M.","Bachmann, M. F."],"key":"fettelschoss-gabriel_active_2019","id":"fettelschoss-gabriel_active_2019","bibbaseid":"fettelschossgabriel-fettelschoss-olomski-birkmann-thoms-bhler-kummer-zeltins-etal-activevaccinationagainstinterleukin5aslongtermtreatmentforinsectbitehypersensitivityinhorses-2019","role":"author","urls":{"Paper":"http://doi.wiley.com/10.1111/all.13659"},"keyword":["Application - Allergy Research","Application - Antibody Validation / Epitope Mapping","Application - Vaccine Development","Country - Latvia","Country - Switzerland","Country - United Kingdom","Other Organisms","PEPperCHIP - Customized - Linear","PEPperMAP - Epitope Mapping - Linear","Sample Type - Serum"],"metadata":{"authorlinks":{}},"downloads":2},"bibtype":"article","biburl":"https://bibbase.org/zotero/PEPperPAPER","creationDate":"2020-07-16T12:28:26.986Z","downloads":2,"keywords":["application - allergy research","application - antibody validation / epitope mapping","application - vaccine development","country - latvia","country - switzerland","country - united kingdom","other organisms","pepperchip - customized - linear","peppermap - epitope mapping - linear","sample type - serum"],"search_terms":["active","vaccination","against","interleukin","long","term","treatment","insect","bite","hypersensitivity","horses","fettelschoss-gabriel","fettelschoss","olomski","birkmann","thoms","bühler","kummer","zeltins","kündig","bachmann"],"title":"Active vaccination against interleukin-5 as long-term treatment for insect-bite hypersensitivity in horses","year":2019,"dataSources":["uik5uKfH7ojkHRgZZ","idrrfXaW5AQj5dNMY","NvXC6TpyECRTzBpu8"]}